Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is expected to see a positive outlook as the company secured capital and development funding, is advancing Tivoxavir marboxil into a human challenge study for influenza, and has potential with its other product candidates in treating COVID, hantavirus, and Ebola. Further potential upside could come from the success of Tivoxavir marboxil as a once-monthly influenza prophylaxis and its potential inclusion in the Strategic National Stockpile. While there are risks involved, such as financing, clinical trial, regulatory, delisting, and bankruptcy risks, the current market cap does not fully reflect the potential value of the company's pipeline and future success.

Bears say

Traws Pharma is facing financial challenges as a result of the negative review of their tivoxavir marboxil program by the MHRA, leading to a deferral of their planned human influenza challenge study. This setback limits the company's visibility for their next value driver and raises concerns about their ability to secure funding, given their cash runway only extends through 1Q27. Additionally, the decrease in the overall market for COVID therapeutics and the decreased emphasis on their COVID program suggest limited potential for financial success in the near future.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Hold based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Hold consensus rating as of Aug 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.